Arca biopharma announces second quarter 2024 financial results and provides corporate update

Westminster, colo., aug. 01, 2024 (globe newswire) -- arca biopharma, inc. (nasdaq: abio), (the “company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2024 financial results and provided a corporate update.
ABIO Ratings Summary
ABIO Quant Ranking